X
Xilio Therapeutics, Inc. (XLO)
NCM – Real Time Price. Currency in USD
8.32
-0.36 (-4.15%)
At close: Mar 27, 2026, 4:00 PM EDT
8.35
+0.03 (0.36%)
After-hours: Mar 27, 2026, 5:35 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
8.32
-0.36 (-4.15%)
At close: Mar 27, 2026, 4:00 PM EDT
8.35
+0.03 (0.36%)
After-hours: Mar 27, 2026, 5:35 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.20 | 6.05 | 10 | |
| Quick ratio | 2.20 | 5.63 | 10 | |
| Debt to Equity | N/A | 0.30 | 1.0 | |
| Debt to Assets | 0.05 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 6.2 | |||
| METRIC | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | 6M | 32M |
| Gross Profit | -1M | -2M | -2M | 5M | 30M |
| Operating Income | -75M | -89M | -79M | -60M | -44M |
| Net Income | -76M | -88M | -76M | -58M | -58M |
| EBITDA | -74M | -87M | -77M | -58M | -42M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 532.25 | 65 | 10 |
| Next quarter | 273.93 | 61.28 | 10 |
| Current year | 546.28 | 55.05 | 10 |
| Next year | -7.8 | 38.78 | 5.5 |
| Weighted average score | 8.9 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 135.85 | -2.79 | 31.25 | -17.58 | 5.5 |
| Y/Y | 742.51 | -16.16 | 50 | -27.87 | 5.5 |
| 3y average | 999 | 6.93 | 50.21 | 29.83 | 8.8 |
| 5y average | 999 | -47.08 | 50.21 | -26.11 | 5.5 |
| Weighted average score | 6.3 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $103.8M significantly exceed its total debt $7.3M, ensuring strong financial flexibility
Total current assets $124.1M exceed Total current liabilities $56.4M, highlighting excellent liquidity
Debt-to-equity ratio (-0.9) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$17.5M limits the company's ability to reinvest or pay down debt